Orexin Antagonists and Drug-Seeking Behavior
Peptides and Addiction
70%
Reduction in cocaine-seeking behavior after OX1R antagonist administration in rats trained to self-administer cocaine under cue-induced reinstatement conditions.
Mahler et al., Neuropsychopharmacology, 2014
Mahler et al., Neuropsychopharmacology, 2014
View as imageIn 1998, Takeshi Sakurai and colleagues identified two neuropeptides produced by a small cluster of neurons in the lateral hypothalamus: orexin-A and orexin-B, also called hypocretin-1 and hypocretin-2.[1] The initial research focused on feeding behavior. Within a decade, the orexin system had become one of the most studied targets in addiction neuroscience. Orexin neurons project directly to the ventral tegmental area (VTA), nucleus accumbens, and prefrontal cortex, the same circuits that drugs of abuse hijack to create compulsive use. Blocking orexin signaling at its receptors, OX1R and OX2R, reduces drug-seeking across multiple substance classes in animal models, and early human trials suggest this translates to clinical benefit. This article covers the preclinical evidence, the receptor pharmacology, and the clinical programs currently testing whether orexin antagonists can treat addiction without the sedation, dependence, or abuse liability of existing medications. For broader context on how peptide systems interact with addictive behavior, see GLP-1 Agonists and Addictive Behavior: The Unexpected Discovery.
Key Takeaways
- Orexin-A and orexin-B are hypothalamic neuropeptides that activate OX1R and OX2R, receptors concentrated in brain regions governing reward, arousal, and stress
- Selective OX1R antagonists (1-SORAs) reduced cue-induced cocaine reinstatement by approximately 70% in preclinical models (Mahler et al., 2014)
- The dual orexin receptor antagonist suvorexant decreased fentanyl self-administration and reduced breakpoint (willingness to work for drug) in rats (Campbell et al., 2020)
- A human laboratory study found suvorexant improved sleep duration by roughly 90 minutes and reduced opioid craving during buprenorphine taper (Huhn et al., 2022)
- Orexin antagonists show reduced abuse liability compared to benzodiazepines and z-drugs in human abuse-potential studies
- NIDA has recognized orexin receptor antagonists among its medication development priorities for substance use disorders
How Orexin Neurons Drive Drug-Seeking
The lateral hypothalamus (LH) has long been called the brain's "reward center," a designation earned partly through electrode stimulation experiments in the 1950s that showed animals would press a lever thousands of times to activate this region. The discovery of orexin neurons in the LH provided a molecular mechanism for how this region drives motivated behavior.
Orexin neurons receive inputs from stress-responsive circuits (the extended amygdala, bed nucleus of the stria terminalis) and from metabolic signals (ghrelin, leptin). They project densely to the VTA, where they excite dopamine neurons that project to the nucleus accumbens.[2] This means orexin neurons sit at a crossroads: they integrate stress, arousal, and energy status, then translate those signals into dopamine-driven motivation.
In 2005, two papers changed the field. Harris and colleagues showed that activation of LH orexin neurons was strongly linked to conditioned preference for environments paired with cocaine or morphine, and that stimulating these neurons reinstated extinguished drug-seeking, an effect blocked by the OX1R antagonist SB-334867.[2] In the same year, Boutrel and colleagues demonstrated that intracerebroventricular injection of orexin-A reinstated cocaine-seeking in rats that had stopped responding, and that this reinstatement was linked to activation of stress pathways including corticotropin-releasing factor (CRF).[3]
These findings established a principle: orexin does not simply make animals feel good. It drives the motivational urgency to seek drugs, especially when environmental cues or stress signals are present.
OX1R vs. OX2R: Why Receptor Selectivity Matters
Orexin-A binds both OX1R and OX2R with roughly equal affinity. Orexin-B preferentially activates OX2R. The two receptors have overlapping but distinct distributions in the brain, and this matters for addiction pharmacology.
OX1R is concentrated in the VTA, locus coeruleus, and prefrontal cortex. Blocking OX1R with selective antagonists (1-SORAs) consistently reduces the motivational and rewarding properties of drugs without causing significant sedation. In cocaine self-administration studies, the 1-SORA SB-334867 reduced progressive-ratio breakpoint (a measure of how hard an animal will work for drug) without affecting food-maintained responding at the same doses.[4]
OX2R is more concentrated in the tuberomammillary nucleus and other arousal-regulating regions. Blocking OX2R produces sedation, which is why OX2R-preferring antagonists and dual antagonists (DORAs) are used as sleep medications. However, OX2R also contributes to drug reward. Studies blocking OX2R alone show reduced ethanol self-administration in alcohol-preferring rats.[5]
DORAs (suvorexant, lemborexant, daridorexant) block both receptors. They reduce drug-seeking and simultaneously improve sleep, which is relevant because sleep disruption is a major predictor of relapse across substance use disorders. The trade-off is daytime sedation at higher doses.
The field is split on which approach will prove more useful clinically. 1-SORAs offer cleaner anti-addiction effects without sedation. DORAs address the insomnia-addiction feedback loop but carry sedation and potential abuse concerns, though human abuse-potential studies show DORAs have substantially lower abuse liability than benzodiazepines or zolpidem.[6]
Preclinical Evidence Across Substances
Cocaine
The cocaine literature is the most developed. Orexin antagonists reduce cocaine self-administration, cue-induced reinstatement, stress-induced reinstatement, and context-driven cocaine seeking. Mahler and colleagues (2014) demonstrated that systemic administration of the OX1R antagonist SB-334867 reduced cue-triggered reinstatement of cocaine seeking by approximately 70%, while leaving food seeking intact.[4] Chemogenetic activation of orexin neurons was sufficient to reinstate cocaine seeking, confirming the causal link.
The DORA suvorexant also attenuated the motivational and hedonic properties of cocaine in rats, reducing progressive-ratio responding and preventing cocaine place preference.[7]
Opioids
Campbell and colleagues (2020) showed that suvorexant reduced fentanyl self-administration in rats and decreased the breakpoint on progressive-ratio schedules, indicating reduced motivation to obtain the drug.[8] Orexin antagonism also attenuated naloxone-precipitated withdrawal signs in morphine-dependent rats, suggesting the orexin system contributes to the aversive withdrawal state that drives relapse.
James and colleagues (2017) reviewed the accumulating evidence and proposed that orexin signaling is particularly important for the transition from casual opioid use to compulsive use, as orexin neuron activation scales with escalating drug intake in extended-access models.[9]
Alcohol
OX1R antagonists reduce ethanol self-administration, conditioned reinstatement, and stress-induced reinstatement of alcohol seeking in multiple rat strains, including alcohol-preferring P rats. Fragale and colleagues (2019) found that intra-VTA infusion of the OX1R antagonist SB-334867 reduced alcohol seeking specifically under conditions of high motivation, with no effect on low-effort consumption, suggesting orexin signaling drives the compulsive aspect of alcohol use rather than casual drinking.[10] This distinction between high-effort and low-effort responding is critical: it suggests orexin antagonists would not eliminate normal pleasurable activities but would specifically dampen the pathological motivation that characterizes addiction. The alcohol research also reveals interactions between orexin and other stress peptides. A 2026 study found that orexin and dynorphin (an endogenous opioid peptide) interact in the posterior paraventricular nucleus of the thalamus to modulate stress-related alcohol seeking, suggesting the orexin system does not operate in isolation but as part of a broader peptide network governing relapse. For more on how GLP-1 agonists affect alcohol consumption through overlapping circuits, see the dedicated article on that topic.
Nicotine
The OX1R antagonist SB-334867 reduced nicotine self-administration and cue-induced reinstatement of nicotine seeking in rats. The effect appears mediated through VTA and insular cortex circuits. Plaza-Zabala and colleagues (2010) demonstrated that systemic SB-334867 dose-dependently reduced nicotine self-administration without altering locomotor activity, and that the effect was specific to drug-reinforced behavior rather than general motor suppression. Microinjection studies localized the effect to the VTA and the insular cortex, a brain region increasingly recognized for its role in interoceptive awareness and craving. Evidence is less extensive than for cocaine or opioids, but the direction is consistent across multiple laboratories.
The Insomnia-Addiction Feedback Loop
Sleep disruption and substance use disorders form a bidirectional cycle. Chronic drug use fragments sleep architecture, and poor sleep increases craving, stress reactivity, and relapse risk. The orexin system sits at the center of this loop: orexin neurons promote wakefulness during the day and are silenced during sleep. During withdrawal from opioids, alcohol, or stimulants, orexin neuron activity becomes dysregulated, contributing to both insomnia and heightened drug-seeking.
This dual role explains why DORAs may have a therapeutic advantage despite their sedative properties. By normalizing sleep while simultaneously dampening reward-circuit activation, DORAs could break the insomnia-relapse cycle at its molecular source. A study by Simmons and colleagues (2020) found that orexin neuron activity during the dark phase (active period in rats) predicted next-day drug-seeking intensity, and that suvorexant administration during the rest phase normalized both sleep architecture and subsequent cocaine seeking. Whether this translates to human circadian patterns remains an active area of investigation.
The connection between sleep and addiction also links this work to other peptide systems. GLP-1 agonists have shown unexpected effects on addictive behavior through distinct but potentially complementary mechanisms, and endogenous opioid peptides play their own role in addiction circuitry. Future research may explore combination approaches targeting multiple peptide systems simultaneously.
From Animal Models to Human Trials
Suvorexant in Opioid Use Disorder
The most advanced clinical data comes from suvorexant studies in opioid use disorder (OUD). Huhn and colleagues (2022) conducted a randomized trial of suvorexant (20 mg) versus placebo in patients undergoing buprenorphine taper. Suvorexant improved total sleep time by approximately 90 minutes, reduced opioid withdrawal severity, and lowered self-reported opioid craving compared to placebo.[11] The study also found that suvorexant lowered diurnal salivary cortisol, suggesting it may attenuate the stress axis dysregulation that drives relapse.
The cortisol finding is worth emphasizing. The hypothalamic-pituitary-adrenal (HPA) axis is chronically dysregulated in OUD, and elevated cortisol during early abstinence is one of the strongest biological predictors of relapse. That suvorexant lowered cortisol alongside improving sleep and reducing craving suggests it may be addressing multiple relapse mechanisms simultaneously rather than just one.
A 2025 review in Translational Psychiatry by Barr and colleagues synthesized the preclinical and clinical evidence and concluded that DORAs and SORAs "may soon become the first non-opioid-based FDA-approved treatments for OUD that address both drug seeking and cravings derived from opioid-associated stimuli, and the aversive withdrawal state that drives relapse."[12] The review also noted that orexin antagonists could be combined with existing medications like buprenorphine rather than replacing them, potentially improving outcomes for patients who remain symptomatic on standard treatment.
Suvorexant in Cocaine Use Disorder
A human laboratory study examined suvorexant maintenance (5, 10, and 20 mg) in non-treatment-seeking individuals with cocaine use disorder. Suvorexant improved sleep quality and reduced stress reactivity at the 20 mg dose. Effects on cocaine craving were mixed: craving decreased in some contexts but not others, possibly because the doses were constrained by the FDA-approved insomnia range and may have been insufficient for full orexin blockade in reward circuits.
Suvorexant in Cannabis Use Disorder
A Phase 4 clinical trial (NCT ongoing, 2024-present) is testing suvorexant for cannabis use disorder, based on the rationale that the insomnia-addiction cycle is particularly relevant for cannabis withdrawal, where sleep disruption is one of the most reported symptoms driving relapse.
Novel Selective OX1R Antagonists
NIDA has funded development of novel, highly selective OX1R antagonists specifically designed for addiction treatment, distinct from the DORAs developed for insomnia. These compounds aim to reduce drug-seeking motivation without causing sedation. A 2024 paper in Addiction Neuroscience described a novel non-opioid selective OX1R antagonist with favorable pharmacokinetic properties for substance use disorder treatment.[13] These compounds have not yet entered human trials.
Why This Approach Is Different from Existing Treatments
Current FDA-approved addiction medications fall into two categories: opioid substitution therapies (methadone, buprenorphine) that carry their own dependence liability, and aversion/blocking agents (naltrexone, disulfiram) that patients frequently discontinue. Neither category addresses the fundamental motivational drive that causes relapse.
Orexin antagonists target a different node in the addiction circuit. Rather than blocking the drug's effect at its receptor (naltrexone) or substituting a safer agonist (methadone), orexin antagonists reduce the upstream motivational signal that says "seek the drug now." This has several potential advantages:
Low abuse liability. DORAs show minimal reinforcing effects in human abuse-potential studies. Participants rated suvorexant's subjective effects as similar to placebo, in contrast to zolpidem, which produced significant "drug liking" scores.[6]
Cross-substance efficacy. Because orexin drives general motivated drug-seeking rather than substance-specific pharmacology, antagonists reduce seeking across opioids, cocaine, alcohol, nicotine, and potentially cannabis. This matters for polysubstance use, which characterizes the majority of real-world addiction.
Sleep improvement. DORAs simultaneously address insomnia, a major relapse risk factor. Insomnia affects 50-75% of patients in early recovery from alcohol, opioid, or stimulant use disorders, and sleep disruption predicts relapse even after months of abstinence.
No opioid mechanism. Orexin antagonists do not activate opioid receptors, making them fundamentally different from methadone and buprenorphine. For patients who refuse opioid-based treatments or for stimulant use disorders where no opioid-based treatment exists, orexin antagonism offers an entirely new pharmacological approach. This is also why NIDA has prioritized their development: the opioid crisis has exposed the limits of existing treatment options, and non-opioid alternatives are urgently needed.
Other peptide-based approaches to addiction are being explored in parallel. Peptide vaccines for nicotine and cocaine take a completely different strategy, using the immune system to neutralize drugs before they reach the brain. Where orexin antagonists target motivation, peptide vaccines target pharmacokinetics. The two approaches could theoretically complement each other.
Limitations and Open Questions
The preclinical evidence is strong but has gaps. Most studies use SB-334867, an OX1R antagonist with known off-target effects (including inhibition of monoamine oxidase and 2B adrenoceptors). Studies with cleaner, next-generation 1-SORAs are needed to confirm selectivity-driven conclusions. Khoo and McNally (2022) highlighted this methodological concern in their review of the translational evidence.[14]
Human trial data remains limited. The Huhn et al. (2022) opioid study enrolled a small sample and used suvorexant within FDA-approved insomnia doses, which may not achieve the receptor occupancy needed for full anti-addiction effects. Whether higher doses or selective compounds would show larger effects is unknown.
Sex differences are poorly characterized. Most preclinical orexin-addiction studies have used male rats. The few studies including females suggest sex-dependent effects on orexin neuron activation during drug seeking, but systematic investigation is lacking.
The orexin system regulates arousal, feeding, energy expenditure, and autonomic function in addition to reward. Long-term consequences of chronic orexin blockade beyond the insomnia indication are not well understood. Weight gain, mood changes, and metabolic effects remain theoretical concerns that require monitoring in extended addiction trials.
DORAs are currently Schedule IV controlled substances in the United States due to concerns about next-day sedation and rare parasomnias (complex sleep behaviors). Whether regulatory agencies will approve a DORA for addiction treatment, or whether 1-SORAs will reach the market first, remains uncertain.
The Bottom Line
Orexin antagonists represent a mechanistically novel approach to addiction treatment. Preclinical data across opioids, cocaine, alcohol, and nicotine consistently shows that blocking orexin receptors reduces drug-seeking, particularly under conditions of high motivation, cue exposure, or stress. Early human trials with the DORA suvorexant show signals for reduced opioid craving, improved sleep, and lower stress hormones during withdrawal. Selective OX1R antagonists designed specifically for addiction are in development but have not yet reached human testing. The clinical evidence, while promising, is early-stage: small samples, short durations, and doses limited by existing insomnia labeling.